Search
forResearch 10 of 1000+
- Management of Dermatologic Toxicities
- 307 Dermatologic toxicities associated with chronic gamma-secretase inhibitor treatment for desmoid tumor
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- MARIO LACOUTURE: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
- Dermatological adverse events with taxane chemotherapy
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- P164 Cutaneous toxicities occurring during amivantamab treatment: the experience of a single large specialist institution
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →